Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener Medizinische Wochenschrift 13-14/2014

01.07.2014 | review

Pyoderma gangrenosum: pathogenetic oriented treatment approaches

verfasst von: MD Prof. Dr. Uwe Wollina, MD, PhD Ass.-Prof. Dr. Georgi Tchernev

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 13-14/2014

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Pyoderma gangrenosum (PG) shows features of autoimmune and autoinflammatory disorders. Genetic defects which affect the inflammasome, and in particular the NLRP3 zone, can cause an abnormal secretion of interleukin 1 (IL-1). IL-1 may be involved in clinical manifestation of certain (genetic) forms of PG. IL-1 receptor antagonists reduce the activity of IL-1α and IL-1β. Mutations in the PSTPIP1 gene have been identified in patients with pyogenic arthritis, pyoderma gangrenosum and acne syndrome. In patients with a pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome these mutations cannot be found and the effect of IL-1 inhibition is questionable. Another upcoming opportunity is targeted therapy by tumor necrosis factor-alfa inhibitors in steroid-resistant patients. This review has been focused on (1) the modern pathogenetic concepts, (2) the currently accepted criteria for differentiating the disease, (3) the target therapy and (4) valuable advice to the clinicians regarding a number of medicaments capable of aggravating or inducing the PG.
Literatur
1.
Zurück zum Zitat Brunsting LA, Goeckerman WH, O’Leary PA. Pyoderma [ecthyma] gangrenosum: Clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syph. 1930;22:655–80. Brunsting LA, Goeckerman WH, O’Leary PA. Pyoderma [ecthyma] gangrenosum: Clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syph. 1930;22:655–80.
2.
Zurück zum Zitat Tchernev G, Trebing D, Göring H-D, Steinhoff M, Zouboulis CC, Orfanos C. Pyoderma gangrenosum in Crohn’s disease—the role of immunologic parameters and histological data in diagnosis and differential diagnosis. Bulg J Hepatogastroenterol. 2005;7:56–60. Tchernev G, Trebing D, Göring H-D, Steinhoff M, Zouboulis CC, Orfanos C. Pyoderma gangrenosum in Crohn’s disease—the role of immunologic parameters and histological data in diagnosis and differential diagnosis. Bulg J Hepatogastroenterol. 2005;7:56–60.
3.
Zurück zum Zitat Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3:149–58. PubMedCrossRef Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3:149–58. PubMedCrossRef
4.
Zurück zum Zitat Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25:469–84. doi: 10.1016/j.smim.2013.10.008. PubMedCrossRef Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25:469–84. doi: 10.1016/j.smim.2013.10.008. PubMedCrossRef
5.
Zurück zum Zitat Lipsker D, Lenormand C. Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases. Ann Dermatol Venereol. 2012;139:459–67. PubMedCrossRef Lipsker D, Lenormand C. Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases. Ann Dermatol Venereol. 2012;139:459–67. PubMedCrossRef
6.
Zurück zum Zitat Kowalzick L, Bertolini J, Baumann C, Walther B, Truhm B, Eickenscheidt L. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges. 2013;11:447–9. PubMed Kowalzick L, Bertolini J, Baumann C, Walther B, Truhm B, Eickenscheidt L. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges. 2013;11:447–9. PubMed
7.
Zurück zum Zitat Kikuchi N, Hiraiwa T, Ohashi T, Hanami Y, Satoh M, Takenoshita H, et al. Pyoderma gangrenosum possibly triggered by adalimumab. Eur J Dermatol. 2012;22:804–5. PubMed Kikuchi N, Hiraiwa T, Ohashi T, Hanami Y, Satoh M, Takenoshita H, et al. Pyoderma gangrenosum possibly triggered by adalimumab. Eur J Dermatol. 2012;22:804–5. PubMed
8.
Zurück zum Zitat Stichenwirth M, Riedl E, Pehamberger H, Tappeiner G. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon? Arch Dermatol. 2008;144:817–8. PubMedCrossRef Stichenwirth M, Riedl E, Pehamberger H, Tappeiner G. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon? Arch Dermatol. 2008;144:817–8. PubMedCrossRef
9.
Zurück zum Zitat Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, Greebe RJ. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat. 2011;22:261–5. PubMedCrossRef Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, Greebe RJ. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat. 2011;22:261–5. PubMedCrossRef
11.
Zurück zum Zitat Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395–409. PubMedCrossRef Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395–409. PubMedCrossRef
12.
Zurück zum Zitat Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2,402 patients. Medicine (Baltimore). 2008;87:281–93. CrossRef Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2,402 patients. Medicine (Baltimore). 2008;87:281–93. CrossRef
13.
Zurück zum Zitat Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110–9. PubMedCrossRef Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110–9. PubMedCrossRef
14.
Zurück zum Zitat Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132:2166–70. Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132:2166–70.
15.
Zurück zum Zitat Graham JA, Hansen KK, Rabinowitz LG, Esterly NB. Pyoderma gangrenosum in infants and children. Pediatr Dermatol. 1994;11:10–7. PubMedCrossRef Graham JA, Hansen KK, Rabinowitz LG, Esterly NB. Pyoderma gangrenosum in infants and children. Pediatr Dermatol. 1994;11:10–7. PubMedCrossRef
16.
Zurück zum Zitat Callen JP. Pyoderma gangrenosum and related disorders. Adv Dermatol. 1989;4:51–69. PubMed Callen JP. Pyoderma gangrenosum and related disorders. Adv Dermatol. 1989;4:51–69. PubMed
17.
Zurück zum Zitat Wolff K, Stingl G. Pyoderma gangrenosum. In: Freedberg IM, Eisen AZ, Wolff K, Austen FK, Goldsmith LA, Katz SI, et al., editors. Dermatology in general medicine. New York: McGraw Hill; 1999. pp. 1140–8. Wolff K, Stingl G. Pyoderma gangrenosum. In: Freedberg IM, Eisen AZ, Wolff K, Austen FK, Goldsmith LA, Katz SI, et al., editors. Dermatology in general medicine. New York: McGraw Hill; 1999. pp. 1140–8.
18.
Zurück zum Zitat Powell FC, Schroeter AL, Perry HO, Su WP. Direct immunofluorescence in pyoderma gangrenosum. Br J Dermatol. 1983;108:287–93. PubMedCrossRef Powell FC, Schroeter AL, Perry HO, Su WP. Direct immunofluorescence in pyoderma gangrenosum. Br J Dermatol. 1983;108:287–93. PubMedCrossRef
19.
Zurück zum Zitat Shaya S, Kindzelskii AL, Minor J, Moore EC, Todd RF 3rd, Petty HR. Aberrant integrin [CR4; αxβ2; CD11c/CD18] oscillation on neutrophils in a mild form of pyoderma gangrenosum. J Invest Dermatol. 1998;111:154–8. PubMedCrossRef Shaya S, Kindzelskii AL, Minor J, Moore EC, Todd RF 3rd, Petty HR. Aberrant integrin [CR4; αxβ2; CD11c/CD18] oscillation on neutrophils in a mild form of pyoderma gangrenosum. J Invest Dermatol. 1998;111:154–8. PubMedCrossRef
20.
Zurück zum Zitat Adachi Y, Kindzelskii AL, Cookingham G, Shaya S, Moore EC, Todd RF 3 rd. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol. 1998;111:259–68. Adachi Y, Kindzelskii AL, Cookingham G, Shaya S, Moore EC, Todd RF 3 rd. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol. 1998;111:259–68.
21.
Zurück zum Zitat Sams HH, Mitchell MM, Stratton CW, King LE Jr. Culture and immunohistochemical evidence of chlamydia infection in ulcerative pyoderma gangrenosum. J Am Acad Dermatol. 2003;48:966–9. PubMedCrossRef Sams HH, Mitchell MM, Stratton CW, King LE Jr. Culture and immunohistochemical evidence of chlamydia infection in ulcerative pyoderma gangrenosum. J Am Acad Dermatol. 2003;48:966–9. PubMedCrossRef
22.
Zurück zum Zitat Braun-Falco M, Ruzicka T. Skin manifestations in autoinflammatory syndromes. J Dtsch Dermatol Ges. 2011;9:232–46. PubMed Braun-Falco M, Ruzicka T. Skin manifestations in autoinflammatory syndromes. J Dtsch Dermatol Ges. 2011;9:232–46. PubMed
23.
Zurück zum Zitat Lamprecht P, Gross WL. Autoinflammatory syndromes. Internist (Berl). 2009;50:676–84. CrossRef Lamprecht P, Gross WL. Autoinflammatory syndromes. Internist (Berl). 2009;50:676–84. CrossRef
24.
Zurück zum Zitat Contassot E, Beer HD, French LE. Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Med Wkly. 2012;142:w13590. PubMed Contassot E, Beer HD, French LE. Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Med Wkly. 2012;142:w13590. PubMed
25.
Zurück zum Zitat Almeida de jA, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol. 2013;147:155–74. CrossRef Almeida de jA, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol. 2013;147:155–74. CrossRef
26.
27.
Zurück zum Zitat Nesterovitch AB, Hoffman MD, Simon M, Petukhov PA, Tharp MD, Glant TT. Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum. Clin Exp Dermatol. 2011;36:889–95. PubMedCrossRef Nesterovitch AB, Hoffman MD, Simon M, Petukhov PA, Tharp MD, Glant TT. Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum. Clin Exp Dermatol. 2011;36:889–95. PubMedCrossRef
28.
Zurück zum Zitat Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A. 2003;100:13501–6. PubMedCentralPubMedCrossRef Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A. 2003;100:13501–6. PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Hara H, Tsuchiya K, Kawamura I, Fang R, Hernandez-Cuellar E, Shen Y, et al. Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat Immunol. 2013;14:1247–55. PubMedCrossRef Hara H, Tsuchiya K, Kawamura I, Fang R, Hernandez-Cuellar E, Shen Y, et al. Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat Immunol. 2013;14:1247–55. PubMedCrossRef
30.
Zurück zum Zitat Salminen A, Kauppinen A, Hiltunen M, Kaarniranta K. Epigenetic regulation of ASC/TMS1 expression: potential role in apoptosis and inflammasome function. Cell Mol Life Sci. 2014;71:1855–64. PubMedCrossRef Salminen A, Kauppinen A, Hiltunen M, Kaarniranta K. Epigenetic regulation of ASC/TMS1 expression: potential role in apoptosis and inflammasome function. Cell Mol Life Sci. 2014;71:1855–64. PubMedCrossRef
31.
Zurück zum Zitat Müller-Ladner U, Alten R, Heiligenhaus A, Kekow J, Koletzko S, Mrowietz U, et al. “TRECID”, TNFalpha related chronic inflammatory diseases—a new multiple diseases bridging concept. Dtsch Med Wochenschr. 2009;134:2132–6. PubMedCrossRef Müller-Ladner U, Alten R, Heiligenhaus A, Kekow J, Koletzko S, Mrowietz U, et al. “TRECID”, TNFalpha related chronic inflammatory diseases—a new multiple diseases bridging concept. Dtsch Med Wochenschr. 2009;134:2132–6. PubMedCrossRef
32.
33.
Zurück zum Zitat Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1–14. PubMedCrossRef Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1–14. PubMedCrossRef
34.
Zurück zum Zitat Schadt CR, Callen JP. Management of neutrophilic dermatoses. Dermatol Ther. 2012;25:158–72. PubMedCrossRef Schadt CR, Callen JP. Management of neutrophilic dermatoses. Dermatol Ther. 2012;25:158–72. PubMedCrossRef
35.
Zurück zum Zitat Al Ghazal PH, Herberger K, Schaller J, Strölin A, Hoff NP, Goerge T, et al. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis. 2013;8:136. PubMedCentralPubMedCrossRef Al Ghazal PH, Herberger K, Schaller J, Strölin A, Hoff NP, Goerge T, et al. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis. 2013;8:136. PubMedCentralPubMedCrossRef
36.
Zurück zum Zitat Powell F, Schroeter A, Su W, Perry H. Pyoderma gangrenosum: a review of 86 patients. Q J Med. 1985;55:173–86. PubMed Powell F, Schroeter A, Su W, Perry H. Pyoderma gangrenosum: a review of 86 patients. Q J Med. 1985;55:173–86. PubMed
37.
Zurück zum Zitat Seitz CS, Berens N, Bröcker EB, Trautmann A. Leg ulceration in rheumatoid arthritis—an underreported multicausal complication with considerable morbidity: analysis of thirty-six patients and review of the literature. Dermatology. 2010;220:268–73. PubMedCrossRef Seitz CS, Berens N, Bröcker EB, Trautmann A. Leg ulceration in rheumatoid arthritis—an underreported multicausal complication with considerable morbidity: analysis of thirty-six patients and review of the literature. Dermatology. 2010;220:268–73. PubMedCrossRef
38.
Zurück zum Zitat Hasegawa M, Nagai Y, Sogabe Y, Hattori T, Inoue C, Okada E, et al. Clinical analysis of leg ulcers and gangrene in rheumatoid arthritis. J Dermatol. 2013;40:949–54. PubMedCrossRef Hasegawa M, Nagai Y, Sogabe Y, Hattori T, Inoue C, Okada E, et al. Clinical analysis of leg ulcers and gangrene in rheumatoid arthritis. J Dermatol. 2013;40:949–54. PubMedCrossRef
39.
Zurück zum Zitat Chia HY, Tang MB. Chronic leg ulcers in adult patients with rheumatological diseases—a 7-year retrospective review. Int Wound J. 2012;doi: 10.1111/iwj.12012. [Epub ahead of print] Chia HY, Tang MB. Chronic leg ulcers in adult patients with rheumatological diseases—a 7-year retrospective review. Int Wound J. 2012;doi: 10.1111/iwj.12012. [Epub ahead of print]
40.
Zurück zum Zitat Wollina U, Hein G. Lupus erythematosus: uncommon presentations. Clin Dermatol. 2005;23:470–9. PubMedCrossRef Wollina U, Hein G. Lupus erythematosus: uncommon presentations. Clin Dermatol. 2005;23:470–9. PubMedCrossRef
41.
Zurück zum Zitat Reddy V, Dziadzio M, Hamdulay S, Boyce S, Prasad N, Keat A. Lupus and leg ulcers–a diagnostic quandary. Clin Rheumatol. 2007;26:1173–5. PubMedCrossRef Reddy V, Dziadzio M, Hamdulay S, Boyce S, Prasad N, Keat A. Lupus and leg ulcers–a diagnostic quandary. Clin Rheumatol. 2007;26:1173–5. PubMedCrossRef
42.
Zurück zum Zitat Feld J, Bergman R, Weltfriend S, Zisman D. Pyoderma gangrenosum in a patient with systemic sclerosis. J Rheumatol. 2012;39:197. PubMedCrossRef Feld J, Bergman R, Weltfriend S, Zisman D. Pyoderma gangrenosum in a patient with systemic sclerosis. J Rheumatol. 2012;39:197. PubMedCrossRef
43.
Zurück zum Zitat Fujikura M, Ohtsuka T, Oyamada Y. Systemic sclerosis in association with peristomal pyoderma gangrenosum. Br J Dermatol. 2007;157:618–9. PubMedCrossRef Fujikura M, Ohtsuka T, Oyamada Y. Systemic sclerosis in association with peristomal pyoderma gangrenosum. Br J Dermatol. 2007;157:618–9. PubMedCrossRef
44.
Zurück zum Zitat Shah M, Lewis FM, Harrington CI. Scrotal pyoderma gangrenosum associated with dermatomyositis. Clin Exp Dermatol. 1996;21:151–3. PubMedCrossRef Shah M, Lewis FM, Harrington CI. Scrotal pyoderma gangrenosum associated with dermatomyositis. Clin Exp Dermatol. 1996;21:151–3. PubMedCrossRef
45.
Zurück zum Zitat Zycinska K, Wardyn K, Zielonka TM, Nitsch-Osuch A, Smolarczyk R. Cutaneous changes: an initial manifestation of pulmonary Wegener’s granulomatosis. Adv Exp Med Biol. 2013;755:307–10. PubMedCrossRef Zycinska K, Wardyn K, Zielonka TM, Nitsch-Osuch A, Smolarczyk R. Cutaneous changes: an initial manifestation of pulmonary Wegener’s granulomatosis. Adv Exp Med Biol. 2013;755:307–10. PubMedCrossRef
46.
Zurück zum Zitat Halac U, Al Dhaybi R, Powell J, Bouron-Dal Soglio D, Alvarez F. Unusual association between autoimmune hepatitis and severe pyoderma gangrenosum. J Pediatr Gastroenterol Nutr. 2010;50:219–21. PubMedCrossRef Halac U, Al Dhaybi R, Powell J, Bouron-Dal Soglio D, Alvarez F. Unusual association between autoimmune hepatitis and severe pyoderma gangrenosum. J Pediatr Gastroenterol Nutr. 2010;50:219–21. PubMedCrossRef
47.
Zurück zum Zitat Chandrasekhara PK, Jayachandran NV, Thomas J, Agrawal S, Narsimulu G. Successful treatment of pyoderma gangrenosum associated with juvenile idiopathic arthritis with a combination of topical tacrolimus and oral prednisolone. Clin Rheumatol. 2009;28:489–90. PubMedCrossRef Chandrasekhara PK, Jayachandran NV, Thomas J, Agrawal S, Narsimulu G. Successful treatment of pyoderma gangrenosum associated with juvenile idiopathic arthritis with a combination of topical tacrolimus and oral prednisolone. Clin Rheumatol. 2009;28:489–90. PubMedCrossRef
48.
Zurück zum Zitat Ravic-Nikolic A, Milicic V, Ristic G, Jovovic-Dagovic B. Pyoderma gangrenosum associated with Sjögren syndrome. Eur J Dermatol. 2009;19:392–3. PubMed Ravic-Nikolic A, Milicic V, Ristic G, Jovovic-Dagovic B. Pyoderma gangrenosum associated with Sjögren syndrome. Eur J Dermatol. 2009;19:392–3. PubMed
49.
Zurück zum Zitat Richetta AG, D’Epiro S, Mattozzi C, Giancristoforo S, Calvieri S. Folgoration as an example of pathergy in a patient affected by pyoderma gangrenosum and Takayasu’s arteritis. Dermatol Res Pract. 2009;2009:393452. Richetta AG, D’Epiro S, Mattozzi C, Giancristoforo S, Calvieri S. Folgoration as an example of pathergy in a patient affected by pyoderma gangrenosum and Takayasu’s arteritis. Dermatol Res Pract. 2009;2009:393452.
50.
Zurück zum Zitat Dejardin Botelho A, Delesalle F, Delaporte E, Wallaert B. Pyoderma gangrenosum and Churg-Strauss syndrome. Rev Med Interne. 2007;28:564–5. PubMedCrossRef Dejardin Botelho A, Delesalle F, Delaporte E, Wallaert B. Pyoderma gangrenosum and Churg-Strauss syndrome. Rev Med Interne. 2007;28:564–5. PubMedCrossRef
51.
Zurück zum Zitat Mehta AJ, Charman CR. Pyoderma gangrenosum in association with autoimmune neutropenia of infancy. Pediatr Dermatol. 2008;25:620–2. PubMedCrossRef Mehta AJ, Charman CR. Pyoderma gangrenosum in association with autoimmune neutropenia of infancy. Pediatr Dermatol. 2008;25:620–2. PubMedCrossRef
52.
Zurück zum Zitat Coors EA, von den Driesch P. Pyoderma gangrenosum in a patient with autoimmune haemolytic anaemia and complement deficiency. Br J Dermatol. 2000;143:154–6. PubMedCrossRef Coors EA, von den Driesch P. Pyoderma gangrenosum in a patient with autoimmune haemolytic anaemia and complement deficiency. Br J Dermatol. 2000;143:154–6. PubMedCrossRef
53.
Zurück zum Zitat Necas M, Semrádova V, Vaskù V. Pyoderma gangraenosum associated with autoimmune thyreopathy and hyperandrogenic syndrome. Acta Dermatovenerol Alp Panonica Adriat. 2005;14:57–60. Necas M, Semrádova V, Vaskù V. Pyoderma gangraenosum associated with autoimmune thyreopathy and hyperandrogenic syndrome. Acta Dermatovenerol Alp Panonica Adriat. 2005;14:57–60.
54.
Zurück zum Zitat Livideanu C, Lipsker D, Paul C, Juillard J, Schubert B. Pyoderma gangrenosum as initial manifestation of Graves’ disease. Clin Exp Dermatol. 2006;31:659–61. PubMedCrossRef Livideanu C, Lipsker D, Paul C, Juillard J, Schubert B. Pyoderma gangrenosum as initial manifestation of Graves’ disease. Clin Exp Dermatol. 2006;31:659–61. PubMedCrossRef
55.
Zurück zum Zitat Matis WL, Ellis CN, Griffiths CEM, Lazarus GS. Treatment of pyoderma gangrenosum with cyclosporin. Arch Dermatol. 1992;128:1060–4. PubMedCrossRef Matis WL, Ellis CN, Griffiths CEM, Lazarus GS. Treatment of pyoderma gangrenosum with cyclosporin. Arch Dermatol. 1992;128:1060–4. PubMedCrossRef
56.
Zurück zum Zitat O’Donnell B, Powell FC. Cyclosporin treatment of pyoderma gangrenosum. J Am Acad Dermatol. 1991;24:141–3. O’Donnell B, Powell FC. Cyclosporin treatment of pyoderma gangrenosum. J Am Acad Dermatol. 1991;24:141–3.
57.
Zurück zum Zitat Zumdick M, Goerz G, Schuppe HC, Milde P, Ruzicka T. Niedrig dosierte Cyclosporin-A-Therapie bei Pyoderma gangraenosum. Erfahrungen bei 6 Patienten. Hautarzt. 1995;46:697–701. PubMedCrossRef Zumdick M, Goerz G, Schuppe HC, Milde P, Ruzicka T. Niedrig dosierte Cyclosporin-A-Therapie bei Pyoderma gangraenosum. Erfahrungen bei 6 Patienten. Hautarzt. 1995;46:697–701. PubMedCrossRef
58.
Zurück zum Zitat Van den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137:1000–5. PubMedCrossRef Van den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137:1000–5. PubMedCrossRef
59.
Zurück zum Zitat Prystowsky JH, Kahn SN, Lazarus GS. Present status of pyoderma gangrenosum. Arch Dermatol. 1989;125:57–64. PubMedCrossRef Prystowsky JH, Kahn SN, Lazarus GS. Present status of pyoderma gangrenosum. Arch Dermatol. 1989;125:57–64. PubMedCrossRef
60.
Zurück zum Zitat Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol. 1995;32:241–7. PubMedCrossRef Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol. 1995;32:241–7. PubMedCrossRef
61.
Zurück zum Zitat Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs. 2000;60:273–92. PubMedCrossRef Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs. 2000;60:273–92. PubMedCrossRef
62.
Zurück zum Zitat Wollina U, Karamfilov T. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol Venereol. 2000;14:187–90. PubMedCrossRef Wollina U, Karamfilov T. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol Venereol. 2000;14:187–90. PubMedCrossRef
63.
Zurück zum Zitat Daniels NH, Callen JP. Mycophenolate mofetil is an effective treatment for peristomal pyoderma gangrenosum. Arch Dermatol. 2004;140:1427–9. PubMedCrossRef Daniels NH, Callen JP. Mycophenolate mofetil is an effective treatment for peristomal pyoderma gangrenosum. Arch Dermatol. 2004;140:1427–9. PubMedCrossRef
64.
Zurück zum Zitat Lee MR, Cooper AJ. Mycophenolate mofetil in pyoderma ganrenosum. J Dermatolog Treat. 2004;15:303–7. PubMedCrossRef Lee MR, Cooper AJ. Mycophenolate mofetil in pyoderma ganrenosum. J Dermatolog Treat. 2004;15:303–7. PubMedCrossRef
65.
Zurück zum Zitat Baumgart DC, Wiedenmann B, Dignass AU. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus [FK506] in ulcerative colitis. Inflamm Bowel Dis. 2004;10:421–4. PubMedCrossRef Baumgart DC, Wiedenmann B, Dignass AU. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus [FK506] in ulcerative colitis. Inflamm Bowel Dis. 2004;10:421–4. PubMedCrossRef
66.
Zurück zum Zitat Kontochristopoulos GJ, Stavropoulos PG, Gregoriou S, Zakopoulou N. Treatment of pyoderma gangrenosum with low-dose colchicine. Dermatology. 2004;209:233–6. PubMedCrossRef Kontochristopoulos GJ, Stavropoulos PG, Gregoriou S, Zakopoulou N. Treatment of pyoderma gangrenosum with low-dose colchicine. Dermatology. 2004;209:233–6. PubMedCrossRef
67.
Zurück zum Zitat Schmidt C, Wittig BM, Moser C, Zeitz M, Stallmach A. Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn’s disease. Aliment Pharmacol Ther. 2006;24:343–50. PubMedCrossRef Schmidt C, Wittig BM, Moser C, Zeitz M, Stallmach A. Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn’s disease. Aliment Pharmacol Ther. 2006;24:343–50. PubMedCrossRef
68.
Zurück zum Zitat Budde K, Glander P, Diekmann F, Waiser J, Fritsche L, Dragun D, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother. 2004;5:1333–45. PubMedCrossRef Budde K, Glander P, Diekmann F, Waiser J, Fritsche L, Dragun D, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother. 2004;5:1333–45. PubMedCrossRef
69.
Zurück zum Zitat Fujimoto E, Fujimoto N, Kuroda K, Tajima S. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol. 2004;151:1090–2. PubMedCrossRef Fujimoto E, Fujimoto N, Kuroda K, Tajima S. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol. 2004;151:1090–2. PubMedCrossRef
70.
Zurück zum Zitat Mori S, Nagashima M, Yoshida K, Yoshino K, Aoki M, Kawana S, et al. Granulocyte adsorptive apheresis for leg ulcers complicated by rheumatoid arthritis: a report on three successfully treated cases. Int J Dermatol. 2004;43:732–5. PubMedCrossRef Mori S, Nagashima M, Yoshida K, Yoshino K, Aoki M, Kawana S, et al. Granulocyte adsorptive apheresis for leg ulcers complicated by rheumatoid arthritis: a report on three successfully treated cases. Int J Dermatol. 2004;43:732–5. PubMedCrossRef
71.
Zurück zum Zitat Girolomoni G, Pastore S, Albanesi C, Cavani A. Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases. Curr Opin Investig Drugs. 2002;3:1590–5. PubMed Girolomoni G, Pastore S, Albanesi C, Cavani A. Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases. Curr Opin Investig Drugs. 2002;3:1590–5. PubMed
72.
Zurück zum Zitat Mimouni D, Anhalt GJ, Kouba DJ, Nousari HC. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol. 2003;148:813–6. PubMedCrossRef Mimouni D, Anhalt GJ, Kouba DJ, Nousari HC. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol. 2003;148:813–6. PubMedCrossRef
73.
Zurück zum Zitat Sapienza MS, Cohen S, Dimarino AJ. Treatment of pyoderma gangrenosum with infliximab in Crohn’s disease. Dig Dis Sci. 2004;49:1454–7. PubMedCrossRef Sapienza MS, Cohen S, Dimarino AJ. Treatment of pyoderma gangrenosum with infliximab in Crohn’s disease. Dig Dis Sci. 2004;49:1454–7. PubMedCrossRef
74.
Zurück zum Zitat Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int. 2005;25:406–10. PubMedCrossRef Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int. 2005;25:406–10. PubMedCrossRef
75.
Zurück zum Zitat Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol. 2006;54(Suppl 2):128–34. CrossRef Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol. 2006;54(Suppl 2):128–34. CrossRef
76.
Zurück zum Zitat Hinterberger L, Müller CS, Vogt T, Pföhler C. Adalimumab: a treatment option for pyoderma gangrenosum after failure of systemic standard therapies. Dermatol Ther (Heidelb). 2012;2(1):6. CrossRef Hinterberger L, Müller CS, Vogt T, Pföhler C. Adalimumab: a treatment option for pyoderma gangrenosum after failure of systemic standard therapies. Dermatol Ther (Heidelb). 2012;2(1):6. CrossRef
77.
Zurück zum Zitat Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10:89–102. PubMed Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10:89–102. PubMed
78.
Zurück zum Zitat Steiger S, Harper JL. Mechanisms of spontaneous resolution of acute gouty inflammation. Curr Rheumatol Rep. 2014;16:392. PubMedCrossRef Steiger S, Harper JL. Mechanisms of spontaneous resolution of acute gouty inflammation. Curr Rheumatol Rep. 2014;16:392. PubMedCrossRef
79.
Zurück zum Zitat Tavares AH, Magalhães KG, Almeida RD, Correa R, Burgel PH, Bocca AL. NLRP3 Inflammasome activation by Paracoccidioides brasiliensis. PLoS Negl Trop Dis. 2013;7:e2595. PubMedCentralPubMedCrossRef Tavares AH, Magalhães KG, Almeida RD, Correa R, Burgel PH, Bocca AL. NLRP3 Inflammasome activation by Paracoccidioides brasiliensis. PLoS Negl Trop Dis. 2013;7:e2595. PubMedCentralPubMedCrossRef
80.
Zurück zum Zitat Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003–18. PubMedCrossRef Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003–18. PubMedCrossRef
81.
82.
Zurück zum Zitat Mao L, Zhang L, Li H, Chen W, Wang H, Wu S, et al. Pathogenic fungus Microsporum canis activates the NLRP3 inflammasome. Infect Immun. 2014;82:882–92. PubMedPubMedCentralCrossRef Mao L, Zhang L, Li H, Chen W, Wang H, Wu S, et al. Pathogenic fungus Microsporum canis activates the NLRP3 inflammasome. Infect Immun. 2014;82:882–92. PubMedPubMedCentralCrossRef
83.
Zurück zum Zitat Miao EA, Leaf IA, Treuting PM, Mao DP, Dors M, Sarkar A, et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol. 2010;11:1136–42. PubMedCentralPubMedCrossRef Miao EA, Leaf IA, Treuting PM, Mao DP, Dors M, Sarkar A, et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol. 2010;11:1136–42. PubMedCentralPubMedCrossRef
84.
Zurück zum Zitat Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161:1199–201. PubMedCrossRef Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161:1199–201. PubMedCrossRef
85.
Zurück zum Zitat Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)–a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409–15. PubMedCrossRef Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)–a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409–15. PubMedCrossRef
86.
Zurück zum Zitat Baumgart DC, Wiedenmann B, Dignass AU. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus [FK506] in ulcerative colitis. Inflamm Bowel Dis. 2004;10:421–4. PubMedCrossRef Baumgart DC, Wiedenmann B, Dignass AU. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus [FK506] in ulcerative colitis. Inflamm Bowel Dis. 2004;10:421–4. PubMedCrossRef
87.
Zurück zum Zitat Khurrum Baig M, Marquez H, Nogueras JJ, Weiss EG, Wexner SD. Topical tracrolimus [FK506] in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn’s disease: report of two cases. Colorectal Dis. 2004;6:250–3. PubMedCrossRef Khurrum Baig M, Marquez H, Nogueras JJ, Weiss EG, Wexner SD. Topical tracrolimus [FK506] in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn’s disease: report of two cases. Colorectal Dis. 2004;6:250–3. PubMedCrossRef
88.
Zurück zum Zitat Wollina U. Letter to the editor: Temporary renal insufficiency associated with topical tacrolimus treatment of multilocal pyoderma gangrenosum. J Dermatol Case Rep. 2013;7:106–7. PubMedCentralPubMed Wollina U. Letter to the editor: Temporary renal insufficiency associated with topical tacrolimus treatment of multilocal pyoderma gangrenosum. J Dermatol Case Rep. 2013;7:106–7. PubMedCentralPubMed
89.
Zurück zum Zitat Neiderer K, Martin B, Hoffman S, Jolley D, Dancho J. A mechanically powered negative pressure device used in conjunction with a bioengineered cell-based product for the treatment of pyoderma gangrenosum: a case report. Ostomy Wound Manage. 2012;58:44–8. PubMed Neiderer K, Martin B, Hoffman S, Jolley D, Dancho J. A mechanically powered negative pressure device used in conjunction with a bioengineered cell-based product for the treatment of pyoderma gangrenosum: a case report. Ostomy Wound Manage. 2012;58:44–8. PubMed
90.
Zurück zum Zitat Hill DS, O’Neill JK, Toms A, Watts AM. Pyoderma gangrenosum: a report of a rare complication after knee arthroplasty requiring muscle flap cover supplemented by negative pressure therapy and hyperbaric oxygen. J Plast Reconstr Aesthet Surg. 2011;64:1528–32. Hill DS, O’Neill JK, Toms A, Watts AM. Pyoderma gangrenosum: a report of a rare complication after knee arthroplasty requiring muscle flap cover supplemented by negative pressure therapy and hyperbaric oxygen. J Plast Reconstr Aesthet Surg. 2011;64:1528–32.
91.
Zurück zum Zitat Ghersi MM, Ricotti C, Nousari CH, Newman MI. Negative pressure dressing in the management of pyoderma gangrenosum ulcer. Arch Dermatol. 2007;143:1249–51. PubMedCrossRef Ghersi MM, Ricotti C, Nousari CH, Newman MI. Negative pressure dressing in the management of pyoderma gangrenosum ulcer. Arch Dermatol. 2007;143:1249–51. PubMedCrossRef
92.
Zurück zum Zitat Mir-Bonafé JM, Blanco-Barrios S, Romo-Melgar A, Santos-Briz A, Fernández-López E. Photoletter to the editor: Localized pyoderma gangrenosum after interferon-alpha2b injections. J Dermatol Case Rep. 2012;6:98–9. PubMedCentralPubMedCrossRef Mir-Bonafé JM, Blanco-Barrios S, Romo-Melgar A, Santos-Briz A, Fernández-López E. Photoletter to the editor: Localized pyoderma gangrenosum after interferon-alpha2b injections. J Dermatol Case Rep. 2012;6:98–9. PubMedCentralPubMedCrossRef
93.
Zurück zum Zitat ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol. 2008;159:242–3. PubMedCrossRef ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol. 2008;159:242–3. PubMedCrossRef
94.
Zurück zum Zitat Nadauld LD, Miller MB, Srinivas S. Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol. 2011;29:e266–7. PubMedCrossRef Nadauld LD, Miller MB, Srinivas S. Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol. 2011;29:e266–7. PubMedCrossRef
95.
Zurück zum Zitat Sagara R, Kitami A, Nakada T, Iijima M. Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions. Int J Dermatol. 2006;45:1002–3. PubMedCrossRef Sagara R, Kitami A, Nakada T, Iijima M. Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions. Int J Dermatol. 2006;45:1002–3. PubMedCrossRef
96.
Zurück zum Zitat Bustillo I, Kaley K, Saif MW. Rash associated with the use of pegylated filgrastim in a patient with advanced pancreatic cancer. Cutan Ocul Toxicol. 2009;28:181–4. PubMedCrossRef Bustillo I, Kaley K, Saif MW. Rash associated with the use of pegylated filgrastim in a patient with advanced pancreatic cancer. Cutan Ocul Toxicol. 2009;28:181–4. PubMedCrossRef
97.
Zurück zum Zitat Tinoco MP, Tamler C, Maciel G, Soares D, Avelleira JC, Azulay D. Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic. Int J Dermatol. 2008;47:953–6. PubMedCrossRef Tinoco MP, Tamler C, Maciel G, Soares D, Avelleira JC, Azulay D. Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic. Int J Dermatol. 2008;47:953–6. PubMedCrossRef
98.
Zurück zum Zitat Freiman A, Brassard A. Pyoderma gangrenosum associated with isotretinoin therapy. J Am Acad Dermatol. 2006;55:107–8. CrossRef Freiman A, Brassard A. Pyoderma gangrenosum associated with isotretinoin therapy. J Am Acad Dermatol. 2006;55:107–8. CrossRef
99.
Zurück zum Zitat Hong SB, Lee MH. A case of propylthiouracil-induced pyoderma gangrenosum associated with antineutrophil cytoplasmic antibody. Dermatology. 2004;208:339–41. PubMedCrossRef Hong SB, Lee MH. A case of propylthiouracil-induced pyoderma gangrenosum associated with antineutrophil cytoplasmic antibody. Dermatology. 2004;208:339–41. PubMedCrossRef
100.
Zurück zum Zitat Srebrnik A, Shachar E, Brenner S. Suspected induction of a pyoderma gangrenosum-like eruption due to sulpiride treatment. Cutis. 2001;67:253–6. PubMed Srebrnik A, Shachar E, Brenner S. Suspected induction of a pyoderma gangrenosum-like eruption due to sulpiride treatment. Cutis. 2001;67:253–6. PubMed
Metadaten
Titel
Pyoderma gangrenosum: pathogenetic oriented treatment approaches
verfasst von
MD Prof. Dr. Uwe Wollina
MD, PhD Ass.-Prof. Dr. Georgi Tchernev
Publikationsdatum
01.07.2014
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 13-14/2014
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-014-0285-x